Announcement on Voluntary Disclosure of D-2570 Receiving Approval to Conduct Phase II Psoriasis Clinical Trial in the United States

About this update from Inventisbio, Co., Ltd. Class A

Announcement on Voluntary Disclosure of D-2570 Receiving Approval to Conduct Phase II Psoriasis Clinical Trial in the United States The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Inventisbio, Co., Ltd. Class A